TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06455631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking, Oral Breast Milk , Kangaroo Care
Description: Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking, Oral Breast Milk , Kangaroo Care
Description: Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
Study: NCT06475495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV101
Description: an autologous fully-human anti-CD19 CAR T-cell immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (active comparator)
Description: anti CD20 monoclonal antibody
Study: NCT06682169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovadicitinib
Description: Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
Study: NCT04077320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Self-Efficacy Training
Description: The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Education
Description: The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
Study: NCT05320952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WellO2
Description: The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
Study: NCT06682169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Metoprolol ester is an organic compound mainly used as an immunosuppressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
Study: NCT05554731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a New Balloon Catheter for Intraairway Hemostasis
Description: In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a New Balloon Catheter for Intraairway Hemostasis
Description: In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional Therapy
Description: A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
Study: NCT06596577

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palliative care needs information
Description: clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default consult order
Description: clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs + a choice to cancel the default palliative care consult order
Study: NCT06631079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NECVAX-NEO1
Description: Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
Study: NCT05970731

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microsponge
Description: Drug delivery using chitosan-based biocompatible microsponge

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microsponge
Description: Drug delivery using chitosan-based biocompatible microsponge
Study: NCT06041997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone restriction
Description: The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
Study: NCT05787652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTEMIS mobile app
Description: Access to a self-regulation based mobile application.
Study: NCT05812794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention.
Study: NCT06110117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterimar Stop & Protect Irritation & Dryness
Description: One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for seven days.
Study: NCT05804396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relivion®
Description: Active stimulation device
Study: NCT05493371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10 mg once daily empagliflozin oral tablets for 12 weeks
Study: NCT06693960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oregano
Description: Oil of oregano administered as a softgel (180 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oregano
Description: Oil of oregano administered as a softgel (180 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oregano
Description: Oil of oregano administered as a softgel (180 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug cocktail
Description: Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug cocktail
Description: Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug cocktail
Description: Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
Study: NCT06695312

Intervention type: OTHER
Group type: OTHER
Intervention: selected exercise program
Description: therapeutic ultrasound, Static neck exercise

Intervention type: OTHER
Group type: OTHER
Intervention: selected exercise program
Description: therapeutic ultrasound, Static neck exercise

Intervention type: DEVICE
Group type: OTHER
Intervention: High Tone Power Therapy
Description: High Tone Power Therapy delivered in cervical region 3 times per week for four weeks
Study: NCT06686316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Hypoxic Gas Mixture
Description: The EG (Experimental Group) will undergo a 6-week intervention protocol of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Hypoxic-Hyperoxic exposure
Description: The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
Study: NCT06692036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Blood Purification (ABP)
Description: Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration and adsorption (CPFA) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, CPFA+RRT (plasma filtration adsorption dialysis, PFAD) treatment is used.
Study: NCT06707129

Intervention type: OTHER
Intervention: life-style
Description: The patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.
Study: NCT06707610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK202
Description: Administered intravenously, once every 3 weeks
Study: NCT06710912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group acceptance and commitment therapy (ACT)
Description: The ACT intervention module utilized in this study was adapted from Hayes foundational work on ACT and Harris. A summary of the general contents and exercises in each week was in accordance with the 6 core processes of Acceptance and Commitment Therapy based on Hayes. It was conducted in the Malay language. The same workbook with guided exercise and homework were used by all the therapists to assure standardization of the intervention to ensure that each group received similar contents in each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard care and follow-up for major depressive disorder
Study: NCT06709560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Continuous Exercise
Description: Participants perform a continuous cycling exercise session on a reclined ergometer at moderate intensity (50% HRR)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vigorous Intensity Continuous Exercise
Description: Participants perform a continuous cycling exercise session on a reclined ergometer, at a vigorous intensity (80% HRR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise Matched for Blood Pressure
Description: Participants perform a cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at moderate intensity (50% HRR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity Continuous Exercise Matched for Blood Pressure
Description: Participants perform a different cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at vigorous intensity (80% HRR).
Study: NCT06710431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AFA-281
Description: AFA-281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281
Description: AFA-281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AFA-281
Description: AFA-281
Study: NCT06710548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revitalize Intervention
Description: A remotely delivered telehealth intervention to address cancer fatigue that is based on an acceptance-based approach. 8 weekly sessions and 2 booster sessions will be conducted by trained psychology doctoral students and will focus on fatigue education, Acceptance and Commitment Therapy (ACT) skills, and behavior changes. Wi-Fi enabled tablets and keyboards will be provided to participants if needed. All sessions will be conducted via the Zoom platform and will either be videotaped or audiotaped.
Study: NCT06707896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR1020-CD8 T cells
Description: TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR1020-CD8 T cells
Description: TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR1020-CD8 T cells
Description: TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR1020-CD8 T cells
Description: TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.
Study: NCT06708741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: High dose oral vitamin D supplementation (50,000 IU/once per month)
Study: NCT06709885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide + Tislelizumab + chemotherapy (CapeOX )
Description: Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CapeOX
Description: 4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
Study: NCT06707948

Intervention type: PROCEDURE
Intervention: Arthroscopic meniscus surgery
Description: Comparison of the incidence of osteoarthritis with conservative treatment as well as arthroscopic partial resection as well as arthroscopic repair surgery for a condition known as posterior meniscus root injury.
Study: NCT05385523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal and Sub-Serratus block technique (RISS)
Description: The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
Study: NCT01374945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearpath Lower GI
Description: Clearpath device for cleaning of colon by irrigation and evacuation
Study: NCT05385523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal and Sub-Serratus block technique (RISS)
Description: The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal and Sub-Serratus block technique (RISS)
Description: The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anaesthesia
Description: Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization.